Post by
edrose on Apr 24, 2020 9:50am
How can a biotech with extremely good phase 2 results to
Treat a condition where there’s no CURRENT TREATMENT and these patients often die without treatment fda granted orphan drug designation,fast tract Be only .02 and ceo/management/board of directors state NOT ONE COMPANY IS INTETESTED IN KLY AND IMPOSSIBLE TO RAISE MONEY
ALSO WHAT HAPPENED TO THE 10 MILLION PRIVATE PLACEMENT
THIS DOESNT ADD UP
Comment by
craiggers83 on Apr 24, 2020 10:28am
where did the ceo/board say this?post a link
Comment by
Jack4000 on Apr 24, 2020 11:42am
This post has been removed in accordance with Community Policy